Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Government Denies Patent Application For Copaxone; Natco Pharma Says Obstacles Removed For Supply Of Generic Version Worldwide

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In a decision that could trigger a bigger battle, the Indian Patent Office has denied a patent application filed by an Israeli company for Copaxone(glatiramer), an innovative drug used in the treatment of multiple sclerosis
Advertisement

Related Content

Teva Appeals In Delhi High Court To Block Natco’s Export Of Glatiramer
Teva Appeals In Delhi High Court To Block Natco’s Export Of Glatiramer
Indian Court Dismisses Teva’s Plea To Halt Natco’s Generic Copaxone Exports
Indian Court Dismisses Teva’s Plea To Halt Natco’s Generic Copaxone Exports
U.S. FDA To Review Mylan's Application For Generic Copaxone; India Partner Natco Expects To Cross More Hurdles
U.S. FDA To Review Mylan's Application For Generic Copaxone; India Partner Natco Expects To Cross More Hurdles
Advertisement
UsernamePublicRestriction

Register

SC071061

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel